Scott E. Coleridge

Mr. Coleridge has served as the CEO of ViOptix, Inc for the past 5 years. A highly experienced medical technology executive, Mr. Coleridge’s recent experience includes serving as Co-Founder of Apple Medical (sold to Cooper Surgical), Executive Vice President, FEI Women’s Health (sold to Barr Laboratoriess, now Teva Pharmaceuticals), developer of the only non-hormonal female contraceptive, Mr. Coleridge has spent more than 20 years starting or being part of the senior management team for several early-stage life science companies, including Kingston Diagnostics, developer of the first whole blood cholesterol test (Licensed to Warner Lambert/Pfizer) and CEO of Synthon Chiragenics (sold to Avecia). After the sale of FEI to Barr Laboratories in 2005, Mr. Coleridge joined Morningside Technology Advisory, LLC. He is also a member of the Board of Directors of Excera Orthopedics and Humanzyme, Inc.